Search

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III

Therapeutic area :

van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. Clin Pharmacokinet. 2021. . [Link to publication]

Our expertise

Lung Diseases Diabetes Endocrinology/Sexual health General modelling CNS Cardiovascular Anti-infectives and immunology Peripheral Nervous System Safety pharmacology Blood disorders Biologicals Oncology Paediatrics Methods Pain Gastrointestinal Diseases Anesthesiology